Commercial-stage biopharmaceutical company ADC Therapeutics SA (ADCT) has a clear slate of near-term clinical and operational catalysts that center on ZYNLONTA's development in relapsed or refractory diffuse large B-cell lymphoma and the company's extended financial runway.
The most immediate focus is on additional LOTIS-7 data in the second half of 2025, LOTIS-5 reaching prespecified progression-free survival (PFS) events by year-end, and preparations that position ZYNLONTA for potential advancement across lines of therapy. These events set the stage for data flow and potential regulatory steps through 2026 and beyond.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.